A Phase II Single Arm Trial Evaluating the Safety and Efficacy of Anhydrous Enol-Oxaloacetate on Improving Cognitive Complaints in Breast Cancer Survivors
Latest Information Update: 07 Nov 2024
At a glance
- Drugs Enol oxaloacetate (Primary)
- Indications Cognition disorders
- Focus Therapeutic Use
Most Recent Events
- 05 Nov 2024 Planned End Date changed from 1 Nov 2025 to 1 Nov 2026.
- 05 Nov 2024 Planned primary completion date changed from 1 Nov 2024 to 1 Nov 2025.
- 07 Dec 2023 Planned End Date changed from 1 Nov 2024 to 1 Nov 2025.